1 Growth Stock Down 40% to Buy and Hold Forever
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market.Novo Nordisk has faced some issues, but even taking those into account, the company's prospects remain excellent. Long-term investors can still safely add this stock to their portfolios and hold it for for the long term.Novo Nordisk's most famous GLP-1 medicines, Wegovy and Ozempic, are helping drive solid top-line growth. In 2024, the company's net sales increased by 25% year over year to 290.4 billion Danish kroner ($42 billion USD). That would be an excellent performance for most drugmakers of this size and would likely lead to a strong stock market performance for the year.Continue reading
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market.
Novo Nordisk has faced some issues, but even taking those into account, the company's prospects remain excellent. Long-term investors can still safely add this stock to their portfolios and hold it for for the long term.
Novo Nordisk's most famous GLP-1 medicines, Wegovy and Ozempic, are helping drive solid top-line growth. In 2024, the company's net sales increased by 25% year over year to 290.4 billion Danish kroner ($42 billion USD). That would be an excellent performance for most drugmakers of this size and would likely lead to a strong stock market performance for the year.
